Details for Patent: 9,604,901

Which drugs does patent 9,604,901 protect, and when does it expire?

Patent 9,604,901 protects ORENITRAM and is included in one NDA.

This patent has fifteen patent family members in seven countries.

Summary for Patent: 9,604,901

Title:	Process to prepare treprostinil, the active ingredient in Remodulin®
Abstract:	This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
Inventor(s):	Hitesh Batra, Sudersan M. TULADHAR, Raju Penmasta, David A. Walsh
Assignee:	United Therapeutics Corp
Application Number:	US14/754,932
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,604,901
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 9,604,901

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-001	Dec 20, 2013		RX	Yes	No	9,604,901			Y	Y
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-005	Oct 7, 2016		RX	Yes	No	9,604,901			Y	Y

International Family Members for US Patent 9,604,901

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2710205
China	101903324
China	103274926
European Patent Office	2252570